» Articles » PMID: 26990931

Cardiotoxicity with Rituximab, Cyclophosphamide, Non-pegylated Liposomal Doxorubicin, Vincristine and Prednisolone compared to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone in Frontline Treatment of Patients with Diffuse...

Overview
Journal Eur J Cancer
Specialty Oncology
Date 2016 Mar 19
PMID 26990931
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chemoimmunotherapy containing rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) is the standard treatment for diffuse large B-cell lymphoma (DLBCL). Doxorubicin may induce early and late cardiotoxicity. Non-pegylated liposomal (NPL) doxorubicin may reduce cardiotoxicity.

Patients And Methods: Patients with untreated CD20+ DLBCL were randomised to conventional R-CHOP chemoimmunotherapy or rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone (R-COMP) with doxorubicin substituted by NPL-doxorubicin. Left ventricular ejection fraction (LVEF) and N-terminal pro B-type natriuretic peptide (NT-proBNP) levels were measured before each treatment cycle and after the end of treatment.

Results: The mean LVEF of 178 and 158 measurements in the R-COMP and R-CHOP arms was 63.31% and 62.25%, respectively (P = 0.167). During treatment the LVEF measurements were below 50% in 10/218 (4.6%) in the R-COMP arm and 31/196 (15.8%) in the R-CHOP arm (P<0.001). Thirty-six of 40 (90%) patients in the R-COMP arm, but only 24/36 (66.7%) in the R-CHOP arm had all NT-proBNP levels below 400 pg/ml during and at the end of treatment (P = 0.013). There were more serious adverse events in the R-CHOP arm (26 versus 40, P = 0.029). Infections were more common (15 versus 28) in the R-CHOP arm.

Interpretation: In patients with normal cardiac function, six cycles of R-CHOP resulted in a low rate of early cardiotoxicity. NPL-doxorubicin did not reduce cardiotoxicity, although cardiac safety signals were elevated in R-CHOP compared to R-COMP.

Funding: Cephalon provided the Arbeitsgemeinschaft Medikamentöse Tumortherapie with NPL-doxorubicin and an unrestricted grant, but was not involved in the study protocol, data acquisition, data analysis or the writing of the paper.

Citing Articles

Doxorubicin or Epirubicin Versus Liposomal Doxorubicin Therapy-Differences in Cardiotoxicity.

Buchalska B, Kaminska K, Kowara M, Sobiborowicz-Sadowska A, Cudnoch-Jedrzejewska A Cardiovasc Toxicol. 2025; 25(2):248-268.

PMID: 39810066 DOI: 10.1007/s12012-024-09952-4.


Cardiovascular Considerations During Cancer Therapy: Gaps in Evidence and Expert Panel Recommendations.

Leong D, Waliany S, Abdel-Qadir H, Atkins K, Neilan T, Lang N JACC CardioOncol. 2025; 6(6):815-834.

PMID: 39801647 PMC: 11711816. DOI: 10.1016/j.jaccao.2024.06.005.


Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma.

Upshaw J, Nelson J, Sweigart B, Rodday A, Kumar A, Konstam M JACC CardioOncol. 2024; 6(2):200-213.

PMID: 38774008 PMC: 11103040. DOI: 10.1016/j.jaccao.2024.02.003.


Analysis of competing risks of cardiovascular death in patients with hepatocellular carcinoma: A population-based study.

Cao L, Wang X, Yan Y, Ning Z, Ma L, Li Y Medicine (Baltimore). 2023; 102(51):e36705.

PMID: 38134062 PMC: 10735158. DOI: 10.1097/MD.0000000000036705.


Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experience.

Mo Z, Deng Y, Bao Y, Liu J, Jiang Y Cancer Med. 2023; 12(24):21709-21724.

PMID: 38054208 PMC: 10757145. DOI: 10.1002/cam4.6730.